Jupiter Topco LLC Buys New Holdings in Neurocrine Biosciences, Inc. $NBIX

Posted by Brian Himes on Aug 27th, 2026

Jupiter Topco LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the second quarter, Holdings Channel reports. The fund purchased 526,341 shares of the company’s stock, valued at approximately $88,707,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 0.5% in the 1st quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock valued at $1,721,000 after purchasing an additional 68 shares in the last quarter. Huntington National Bank grew its stake in shares of Neurocrine Biosciences by 12.6% during the fourth quarter. Huntington National Bank now owns 678 shares of the company’s stock worth $96,000 after purchasing an additional 76 shares in the last quarter. Motley Fool Asset Management LLC grew its stake in shares of Neurocrine Biosciences by 4.8% during the fourth quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock worth $240,000 after purchasing an additional 78 shares in the last quarter. Main Management ETF Advisors LLC increased its holdings in Neurocrine Biosciences by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock valued at $1,111,000 after buying an additional 80 shares during the last quarter. Finally, Westpac Banking Corp increased its holdings in Neurocrine Biosciences by 6.0% in the first quarter. Westpac Banking Corp now owns 1,615 shares of the company’s stock valued at $213,000 after buying an additional 91 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In other news, insider Ingrid Delaet sold 8,433 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $178.72, for a total value of $1,507,145.76. Following the completion of the sale, the insider directly owned 16,225 shares of the company’s stock, valued at approximately $2,899,732. This represents a 34.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the transaction, the insider owned 25,846 shares in the company, valued at approximately $4,141,821.50. This trade represents a 29.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 116,636 shares of company stock worth $19,349,078 over the last ninety days. 4.60% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $156.59 on Thursday. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $186.12. The company has a market capitalization of $15.92 billion, a PE ratio of 22.96, a P/E/G ratio of 0.72 and a beta of 0.39. The company has a fifty day moving average of $166.91 and a two-hundred day moving average of $149.30.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $2.85 EPS for the quarter, topping analysts’ consensus estimates of $1.65 by $1.20. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%.The business had revenue of $959.00 million for the quarter, compared to analysts’ expectations of $891.16 million. During the same quarter in the previous year, the firm earned $1.65 earnings per share. The business’s revenue was up 39.5% compared to the same quarter last year. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 7.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NBIX. Wells Fargo & Company lifted their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Canaccord Genuity Group increased their price objective on Neurocrine Biosciences from $200.00 to $210.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Truist Financial raised their target price on Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Stifel Nicolaus upped their price target on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $200.86.

Check Out Our Latest Analysis on Neurocrine Biosciences

About Neurocrine Biosciences

(Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.